NLS Pharmaceutics (NLSP) Competitors $2.29 +0.03 (+1.33%) Closing price 02/18/2025 04:00 PM EasternExtended Trading$2.27 -0.02 (-0.83%) As of 02/18/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NLSP vs. ELEV, DTIL, IRD, VYNE, GRCE, ATNM, PASG, CLDI, OCX, and UBXShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Elevation Oncology (ELEV), Precision BioSciences (DTIL), Opus Genetics (IRD), VYNE Therapeutics (VYNE), Grace Therapeutics (GRCE), Actinium Pharmaceuticals (ATNM), Passage Bio (PASG), Calidi Biotherapeutics (CLDI), OncoCyte (OCX), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Elevation Oncology Precision BioSciences Opus Genetics VYNE Therapeutics Grace Therapeutics Actinium Pharmaceuticals Passage Bio Calidi Biotherapeutics OncoCyte Unity Biotechnology Elevation Oncology (NASDAQ:ELEV) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Which has preferable earnings and valuation, ELEV or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevation OncologyN/AN/A-$45.70M-$0.82-0.83NLS PharmaceuticsN/AN/A-$12.17MN/AN/A Is ELEV or NLSP more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Elevation OncologyN/A -59.73% -40.05% NLS Pharmaceutics N/A N/A N/A Which has more volatility & risk, ELEV or NLSP? Elevation Oncology has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500. Do analysts recommend ELEV or NLSP? Elevation Oncology presently has a consensus target price of $7.20, suggesting a potential upside of 963.20%. Given Elevation Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Elevation Oncology is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevation Oncology 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of ELEV or NLSP? 83.7% of Elevation Oncology shares are owned by institutional investors. 8.1% of Elevation Oncology shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor ELEV or NLSP? In the previous week, NLS Pharmaceutics had 1 more articles in the media than Elevation Oncology. MarketBeat recorded 1 mentions for NLS Pharmaceutics and 0 mentions for Elevation Oncology. Elevation Oncology's average media sentiment score of 0.99 beat NLS Pharmaceutics' score of -0.20 indicating that Elevation Oncology is being referred to more favorably in the media. Company Overall Sentiment Elevation Oncology Positive NLS Pharmaceutics Neutral Does the MarketBeat Community believe in ELEV or NLSP? Elevation Oncology received 27 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 76.09% of users gave Elevation Oncology an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformElevation OncologyOutperform Votes3576.09% Underperform Votes1123.91% NLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% SummaryElevation Oncology beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.24M$6.87B$5.77B$9.20BDividend YieldN/A2.90%5.29%3.98%P/E RatioN/A9.4226.4419.51Price / SalesN/A260.31449.4569.98Price / CashN/A75.4646.0638.90Price / BookN/A5.477.255.07Net Income-$12.17M$123.25M$3.19B$222.54M7 Day Performance-2.14%1.73%1.41%2.13%1 Month Performance19.90%1.38%3.50%1.63%1 Year Performance397.83%-0.12%20.82%16.41% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$2.29+1.3%N/A+397.8%$8.24MN/A0.006Gap UpELEVElevation Oncology2.6537 of 5 stars$0.62-1.3%$7.20+1,055.9%-77.0%$36.83MN/A-0.7640Gap UpDTILPrecision BioSciences4.5454 of 5 stars$4.79+1.9%$37.67+686.4%-56.5%$36.74M$48.73M79.85200Positive NewsGap UpIRDOpus Genetics2.0986 of 5 stars$1.14-0.9%$8.00+601.8%N/A$35.99M$8.38M-1.0514News CoverageVYNEVYNE Therapeutics2.6366 of 5 stars$2.43+0.8%$6.88+182.9%+10.1%$35.84M$420,000.00-2.8330Gap DownGRCEGrace Therapeutics2.6699 of 5 stars$3.51+8.3%N/AN/A$35.59MN/A-3.48N/AEarnings ReportAnalyst ForecastHigh Trading VolumeATNMActinium Pharmaceuticals1.7201 of 5 stars$1.13+0.9%$7.40+554.9%N/A$35.26M$80,000.00-0.8130Gap UpPASGPassage Bio3.1847 of 5 stars$0.57-3.6%$7.75+1,259.4%-57.7%$35.22MN/A-0.49130Gap UpCLDICalidi Biotherapeutics2.1424 of 5 stars$1.32+1.5%$16.67+1,162.6%N/A$34.93M$50,000.000.0038Gap UpOCXOncoCyte3.3273 of 5 stars$2.07+3.0%$4.42+113.4%-10.0%$34.84M$1.50M0.00120UBXUnity Biotechnology4.0574 of 5 stars$2.04-4.7%$7.33+259.5%+3.6%$34.37M$240,000.00-1.5660Negative NewsGap Up Related Companies and Tools Related Companies Elevation Oncology Alternatives Precision BioSciences Alternatives Opus Genetics Alternatives VYNE Therapeutics Alternatives Grace Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Passage Bio Alternatives Calidi Biotherapeutics Alternatives OncoCyte Alternatives Unity Biotechnology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLSP) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.